Business
Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity
DALLAS, April 20, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for mid-May 2026 to seek feedback on proposed protocol amendments to its ongoing Phase 2 HARMONIC™ clinical trial evaluating LP-300. The amendments are grounded in emerging clinical data demonstrating a meaningful and consistent progression-free survival signal in patients with EGFR Exon 21 L858R-mu
About this update from Lantern Pharma Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/079d5f9ace63cd395dca9dbe05942835"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dLF4k.ONamEx4JYiHNiS4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/079d5f9ace63cd395dca9dbe05942835","width":480,"height":240}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Lantern Pharma Schedules Type C Meeting with the FDA to Advance HARMONIC™ Protocol Amendments Targeting This High-Need Population, Reflecting LP-300’s Novel Mechanism of Action and the Rapidly Evolving Post-TKI Standard of Care","length":227,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Among L858R patients in HARMONIC™, those who completed 6 doses or cycles of LP-300 demonstrated a higher median PFS than the overall L858R cohort and those patients that had only 4 doses or cycles of LP-300","length":206,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":433,"olType":false},{"type":"text","content":"DALLAS, April 20, 2026--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for mid-May 2026 to seek feedback on proposed protocol amendments to its ongoing Phase 2 HARMONIC™ clinical trial evaluating LP-300. The amendments are grounded in emerging clinical data demonstrating a meaningful and consistent progression-free survival signal in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer (NSCLC) who have progressed following any TKI-based treatment (including osimertinib) — a population carrying a particularly poor prognosis and limited remaining therapeutic options. Lantern is seeking the FDA’s scientific guidance to sharpen the trial design around the patients most likely to benefit, and to pursue the most rigorous and efficient development path possible.","length":925,"tagName":"p"},{"type":"text","content":"Emerging Clinical Evidence: A Consistent and Coherent Signal","length":60,"tagName":"p"},{"type":"text","content":"Preliminary clinical data from the HARMONIC™ trial, with a data cutoff of April 13, 2026, have r...